Trial reportJournal of the American Academy of Child and Adolescent Psychiatry2026
Different Changes in Brain Functional Networks Following 12-Week Psychostimulant Treatment in Attention-Deficit/Hyperactivity Disorder Youth With and Without Familial Risk for Bipolar I Disorder.
Trial report in Journal of the American Academy of Child and Adolescent Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02478788 (Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveAlthough psychostimulants are the first-line treatment for attention-deficit/hyperactivity disorder (ADHD) and can normalize associated brain network abnormalities, their neural effects in ADHD youth with a family history of bipolar I disorder (BD) have not yet been systematically investigated.
methodThis study investigated the effects of 12-week mixed amphetamine salts-extended release (MAS-XR) treatment on brain functional networks and symptom changes in ADHD youth with ("high-risk" [HR]) and without ("low-risk" [LR]) a first-degree relative with BD. LR received 12-week open-label MAS-XR and HR were randomized to MAS-XR or placebo (PLA). Healthy controls (HC) were included for comparative purposes. Resting-state functional magnetic resonance imaging scans were acquired at baseline and week 12. Global and nodal network topological metrics were evaluated based on functional connectivity matrices using graph theoretical analysis.
resultsA total of 135 youth were included (HC, n = 45; LR-MAS, n = 46; HR-MAS, n = 28; HR-PLA, n = 16). For comparisons between HR-MAS and LR-MAS groups, significant group-by-time interactions were identified in global efficiency, characteristic path length, left superior parietal gyrus degree, and right amygdala efficiency. Relative to the HC group, all baseline abnormalities were normalized at week-12 in the LR-MAS group, whereas a decrease in right amygdala efficiency uniquely emerged in the HR-MAS group. Significant correlations were identified between changes in network topology and ADHD symptoms. Connectome-based predictive modeling analysis revealed that baseline network dysconnectivity predicted ADHD treatment outcomes in the HR-MAS group only.
conclusionThese findings provide novel evidence that ADHD youth with and without BD familial risk exhibit different changes in brain network topology and associated symptoms following 12 weeks of psychostimulant treatment. PLAIN LANGUAGE SUMMARY: Although psychostimulants can alter brain network connectivity in youth with attention-deficit/hyperactivity disorder (ADHD), their effects in ADHD youth with a family history of bipolar disorder (BD) have not been investigated. This double-blind randomized controlled study compared the effects of psychostimulants on brain networks in a total of 135 youth. Results indicate that ADHD youth with and without BD family history exhibit different brain network changes. These findings suggest that ADHD in conjunction with BD family history may have a neurobiological profile that is distinct from ADHD alone without such a family history. CLINICAL TRIAL REGISTRATION INFORMATION: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (NERF); https://clinicaltrials.gov/study/NCT02478788.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.